Patent details

LUC00157 Product Name: crisaborole, éventuellement sous la forme d'un sel pharmaceutiquement acceptable (conforme aux revendications 30 et 33 du brevet de base)

Basic Information

Publication number:
LUC00157
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP111545752
Legal Status:
Inactive
Application number:
LUC00157
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/19/1421
Marketing Authorization Type:
Marketing Authorization Date:
01/04/2020
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
08/06/2020
First Marketing Authorization date:
01/04/2020
Grant date:
06/07/2021
Activation date:
Publication date:
08/06/2020
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
16/02/2031
SPC Extension Expiration:
16/02/2031
Rejection date:
Withdrawal date:

Owner

From:
08/06/2020
 
 

Name:
Anacor Pharmaceuticals, Inc.
Address:
235 East 42nd Street, NY 10017, New York, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
08/06/2020
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2020/08
Publication date:
13/07/2020
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2021/09
Publication date:
03/08/2021
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
02/03/2026
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
08/06/2020 General Document 31
08/06/2020 Application Form 4
08/06/2020 Publication 1
06/07/2021 Publication 1
06/07/2021 Certificate 1
08/06/2020 General Document 3
08/06/2020 General Document 7
08/06/2020 Outgoing Correspondence 1
06/07/2021 Outgoing Correspondence 1